China Meheco

China Meheco is a state-owned holding listed company on the Shanghai Stock Exchange (stock code: 600056), committed to the development of the pharmaceutical industry and the cause of human health, striving to become a flagship enterprise in China's pharmaceutical and health industry. In recent years, the company has preliminarily established an integrated industrial structure of trade, industry, technology, and service, led by international trade, supported by pharmaceutical manufacturing, and linked by pharmaceutical commerce. The industrial forms cover the entire industry chain, including planting and processing, research and development, production, sales, logistics, import and export trade, academic promotion, and technical services. According to authoritative industry rankings, the company ranked 35th among chemical pharmaceutical enterprises in the 2020 Top 100 List of China Pharmaceutical Industry; China Meheco-Chongqing Pharmaceutical Consortium ranked 5th in the 2020 Top 100 List of Pharmaceutical Distribution. It has received honors and awards such as "Best Board Award of Chinese Listed Companies," "Golden Bull Social Responsibility Award for High-Quality Development of Listed Companies," "Financial Sector 2020-Pharmaceuticals and Biotechnology Industry-ESG Responsibility Enterprise Award," "Top 100 Enterprises Award of Chinese Listed Companies," "Corporate Social Responsibility Award of Chinese Listed Companies," "Annual Responsible Business Leader Award," "70 Years of Economic Merit Award since the Founding of the People's Republic of China," and "Top 500 Philanthropy Enterprises in China 2021."